메뉴 건너뛰기




Volumn 5, Issue 5, 2009, Pages 369-374

Treatment effects of Memantine on language in moderate to severe Alzheimer's disease patients

Author keywords

Alzheimer's disease; Clinical trial; Language; Memantine; Scale; Severe Impairment Battery

Indexed keywords

DONEPEZIL; MEMANTINE; PLACEBO;

EID: 69949154414     PISSN: 15525260     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jalz.2009.05.604     Document Type: Article
Times cited : (42)

References (27)
  • 1
    • 33947676929 scopus 로고    scopus 로고
    • A longitudinal study of language decline in Alzheimer's disease and frontotemporal dementia
    • Blair M., Marczinski C.A., Davis-Faroque N., and Kertesz A. A longitudinal study of language decline in Alzheimer's disease and frontotemporal dementia. J Int Neuropsychol Soc 13 (2007) 237-245
    • (2007) J Int Neuropsychol Soc , vol.13 , pp. 237-245
    • Blair, M.1    Marczinski, C.A.2    Davis-Faroque, N.3    Kertesz, A.4
  • 2
    • 2942512931 scopus 로고    scopus 로고
    • Verbal fluency performance in dementia of the Alzheimer's type: a meta-analysis
    • Henry J.D., Crawford J.R., and Phillips L.H. Verbal fluency performance in dementia of the Alzheimer's type: a meta-analysis. Neuropsychologia 42 (2004) 1212-1222
    • (2004) Neuropsychologia , vol.42 , pp. 1212-1222
    • Henry, J.D.1    Crawford, J.R.2    Phillips, L.H.3
  • 4
    • 84986638429 scopus 로고
    • Symptoms of communication breakdown in dementia: carers' perceptions
    • Powell J.A., Hale M.A., and Bayer A.J. Symptoms of communication breakdown in dementia: carers' perceptions. Eur J Disord Commun 30 (1995) 65-75
    • (1995) Eur J Disord Commun , vol.30 , pp. 65-75
    • Powell, J.A.1    Hale, M.A.2    Bayer, A.J.3
  • 7
    • 69949173231 scopus 로고    scopus 로고
    • Alzheimer's dementia. Coping with communication decline
    • Hendryx-Bedalov P.M. Alzheimer's dementia. Coping with communication decline. J Gerontol Nurs 15 (2000) 37-47
    • (2000) J Gerontol Nurs , vol.15 , pp. 37-47
    • Hendryx-Bedalov, P.M.1
  • 8
    • 35148818907 scopus 로고
    • Assessment of the severely impaired patient: description and validation of a new neuropsychological test battery
    • Saxton J., Swihart A.A., McGonigle-Gibson K.L., Miller V.J., and Boller F. Assessment of the severely impaired patient: description and validation of a new neuropsychological test battery. Psychol Assess 2 (1990) 298-303
    • (1990) Psychol Assess , vol.2 , pp. 298-303
    • Saxton, J.1    Swihart, A.A.2    McGonigle-Gibson, K.L.3    Miller, V.J.4    Boller, F.5
  • 10
    • 0028152357 scopus 로고
    • Severe Impairment Battery. A neuropsychological test for severely demented patient
    • Panisset M., Roudier M., Saxton J., and Boller F. Severe Impairment Battery. A neuropsychological test for severely demented patient. Arch Neurol 51 (1994) 41-45
    • (1994) Arch Neurol , vol.51 , pp. 41-45
    • Panisset, M.1    Roudier, M.2    Saxton, J.3    Boller, F.4
  • 11
    • 0030801505 scopus 로고    scopus 로고
    • The Severe Impairment Battery: concurrent validity and the assessment of longitudinal change in Alzheimer's disease
    • Schmitt F.A., Ashford W., Ernesto C., Saxton J., Schneider L.S., Clark C.M., et al. The Severe Impairment Battery: concurrent validity and the assessment of longitudinal change in Alzheimer's disease. Alzheimer Dis Assoc Disord 11 (1997) 51-56
    • (1997) Alzheimer Dis Assoc Disord , vol.11 , pp. 51-56
    • Schmitt, F.A.1    Ashford, W.2    Ernesto, C.3    Saxton, J.4    Schneider, L.S.5    Clark, C.M.6
  • 13
    • 15044338779 scopus 로고    scopus 로고
    • Failures and successes of NMDA receptor antagonists: molecular basis for the use of open-channel blockers like Memantine in the treatment of acute and chronic neurologic insults
    • Lipton S.A. Failures and successes of NMDA receptor antagonists: molecular basis for the use of open-channel blockers like Memantine in the treatment of acute and chronic neurologic insults. NeuroRx 1 (2004) 101-110
    • (2004) NeuroRx , vol.1 , pp. 101-110
    • Lipton, S.A.1
  • 14
    • 36048984931 scopus 로고    scopus 로고
    • Pharmacotherapy of Alzheimer disease
    • Seow D., and Gauthier S. Pharmacotherapy of Alzheimer disease. Can J Psychiatry 52 (2007) 620-629
    • (2007) Can J Psychiatry , vol.52 , pp. 620-629
    • Seow, D.1    Gauthier, S.2
  • 15
    • 69949164972 scopus 로고    scopus 로고
    • Efficacy of Memantine in patients with moderately severe to severe Alzheimer's disease in Japan (dose-finding study)
    • Homma A, Kitamura S, Yoshimura I. Efficacy of Memantine in patients with moderately severe to severe Alzheimer's disease in Japan (dose-finding study). Eur J Neurol 14.
    • Eur J Neurol , vol.14
    • Homma, A.1    Kitamura, S.2    Yoshimura, I.3
  • 16
    • 34249873186 scopus 로고    scopus 로고
    • A 24-week randomized, controlled trial of Memantine in patients with moderate-to-severe Alzheimer disease
    • van Dyck C.H., Tariot P.N., Meyers B., and Malca Resnick E. A 24-week randomized, controlled trial of Memantine in patients with moderate-to-severe Alzheimer disease. Alzheimer Dis Assoc Disord 14 (2007) 136-143
    • (2007) Alzheimer Dis Assoc Disord , vol.14 , pp. 136-143
    • van Dyck, C.H.1    Tariot, P.N.2    Meyers, B.3    Malca Resnick, E.4
  • 17
    • 0345872128 scopus 로고    scopus 로고
    • Memantine treatment in patients with moderate to severe Alzheimer disease already receiving donepezil. A randomized controlled trial
    • Tariot P.N., Farlow M.R., Grossberg G.T., Graham S.M., McDonald S., and Gergel I. Memantine treatment in patients with moderate to severe Alzheimer disease already receiving donepezil. A randomized controlled trial. JAMA 291 (2004) 317-324
    • (2004) JAMA , vol.291 , pp. 317-324
    • Tariot, P.N.1    Farlow, M.R.2    Grossberg, G.T.3    Graham, S.M.4    McDonald, S.5    Gergel, I.6
  • 19
    • 0016823810 scopus 로고
    • "Mini-Mental State": a practical method for grading the cognitive state of patients for the clinician
    • Folstein M.F., Folstein S.E., and McHugh P.R. "Mini-Mental State": a practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res 12 (1975) 189-198
    • (1975) J Psychiatr Res , vol.12 , pp. 189-198
    • Folstein, M.F.1    Folstein, S.E.2    McHugh, P.R.3
  • 20
    • 0024262650 scopus 로고
    • Functional assessment staging (FAST)
    • Reisberg B. Functional assessment staging (FAST). Psychopharmacol Bull 24 (1988) 653-659
    • (1988) Psychopharmacol Bull , vol.24 , pp. 653-659
    • Reisberg, B.1
  • 21
  • 22
    • 0030771116 scopus 로고    scopus 로고
    • An inventory to assess activities of daily living for clinical trials in Alzheimer's disease
    • Galasko D., Bennet D., Sano M., Ernesto C., Thomas R., Grundman M., et al. An inventory to assess activities of daily living for clinical trials in Alzheimer's disease. Alzheimer Dis Assoc Disord 11 Suppl (1997) S33-S39
    • (1997) Alzheimer Dis Assoc Disord , vol.11 , Issue.SUPPL
    • Galasko, D.1    Bennet, D.2    Sano, M.3    Ernesto, C.4    Thomas, R.5    Grundman, M.6
  • 24
    • 18844409426 scopus 로고    scopus 로고
    • Sufficiently important difference: expanding the framework of clinical significance
    • Barrett B., Brown D., Mundt M., and Brown R. Sufficiently important difference: expanding the framework of clinical significance. Med Decis Making 25 (2005) 250-261
    • (2005) Med Decis Making , vol.25 , pp. 250-261
    • Barrett, B.1    Brown, D.2    Mundt, M.3    Brown, R.4
  • 25
    • 0032754432 scopus 로고    scopus 로고
    • Key methodological features of randomized controlled trials of Alzheimer's disease therapy. Minimal clinically important difference, sample size and trial duration
    • Burback D., Molnar F.J., St John P., and Man-Son-Hing M. Key methodological features of randomized controlled trials of Alzheimer's disease therapy. Minimal clinically important difference, sample size and trial duration. Dement Geriatr Cogn Disord 10 (1999) 534-540
    • (1999) Dement Geriatr Cogn Disord , vol.10 , pp. 534-540
    • Burback, D.1    Molnar, F.J.2    St John, P.3    Man-Son-Hing, M.4
  • 26
    • 33749390540 scopus 로고    scopus 로고
    • Minimal changes in health status questionnaires: distinction between minimally detectable change and minimally important change
    • de Vet H.C., Terwee C.B., Ostelo R.W., Beckermann H., Knol D.L., and Bouter L.M. Minimal changes in health status questionnaires: distinction between minimally detectable change and minimally important change. Health Qual Life Outcomes 4 (2006) 54
    • (2006) Health Qual Life Outcomes , vol.4 , pp. 54
    • de Vet, H.C.1    Terwee, C.B.2    Ostelo, R.W.3    Beckermann, H.4    Knol, D.L.5    Bouter, L.M.6
  • 27
    • 5744242292 scopus 로고    scopus 로고
    • The place of Memantine in the treatment of Alzheimer's disease: a number needed to treat analysis
    • Livingston G., and Katona C. The place of Memantine in the treatment of Alzheimer's disease: a number needed to treat analysis. Int J Geriatr Psychiatry 19 (2004) 919-925
    • (2004) Int J Geriatr Psychiatry , vol.19 , pp. 919-925
    • Livingston, G.1    Katona, C.2


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.